Rchr
J-GLOBAL ID:201901019627037781   Update date: Jan. 30, 2024

Kota Ouchi

オオウチ コウタ | Kota Ouchi
Affiliation and department:
Research field  (1): Tumor diagnostics and therapeutics
Research keywords  (2): biomarker ,  Colorectalcancer
Research theme for competitive and other funds  (4):
  • 2020 - 2023 進行胃癌のDIC併発に関連する遺伝子発現異常の網羅的探索研究
  • 2019 - 2022 Research on pathogenesis of DNA-highly methylated type colorectal cancer and the development of diagnosis and treatment methods
  • 2018 - 2020 Search for novel biomarkers to predict treatment sensitivity in colorectal cancer
  • 2015 - 2018 Study on anti-EGFR antibody-resistant conquest of high DNA methylation type colorectal cancer
Papers (39):
  • Sakura Hiraide Taniguchi, Keigo Komine, Noriko Takenaga, Yuya Yoshida, Keiju Sasaki, Yoshifumi Kawamura, Yuki Kasahara, Kota Ouchi, Hiroo Imai, Ken Saijo, et al. FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma. Anticancer research. 2023. 43. 12. 5699-5704
  • Hiroo Imai, Ken Saijo, Yoshifumi Kawamura, Shuto Kodera, Keigo Komine, Tomoyuki Iwasaki, Noriko Takenaga, Yuki Kasahara, Kota Ouchi, Hidekazu Shirota, et al. Comparison of efficacy and safety between carboplatin-etoposide and cisplatin-etoposide combination therapy in patients with advanced neuroendocrine carcinoma, retrospective study. Oncology. 2023
  • Reio Ueta, Hiroo Imai, Ken Saijo, Yoshifumi Kawamura, Shuto Kodera, Keigo Komine, Kota Ouchi, Yuki Kasahara, Sakura Taniguchi, Yuya Yoshida, et al. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma. Oncology. 2023. 1-8
  • Shonosuke Wakayama, Kota Ouchi, Shin Takahashi, Yasuhide Yamada, Yoshito Komatsu, Ken Shimada, Tatsuro Yamaguchi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka. TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer. Clinical colorectal cancer. 2023
  • Shin Takahashi, Kota Ouchi, Yasuhiro Sakamoto, Takahiro Mori, Hideki Shimodaira, Masahiro Takahashi, Hisatsugu Ohori, Chieko Kudo, Yoshikazu Takahashi, Hiroo Imai, et al. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201. Journal of Gastrointestinal Oncology. 2023. 14. 2. 676-691
more...
MISC (29):
  • 梅垣翔, 高橋信, 平出桜, 沖田啓, 笠原佑記, 大内康太, 西條憲, 高橋昌宏, 高橋雅信, 石岡千加史. 再発または遠隔転移を有する頭頸部癌に対するnivolumabの有効性および安全性に関する検討. 日本内科学会雑誌. 2018. 107. Suppl. 272-272
  • 大内康太, 高橋信, 近松園子, 伊藤祝栄, 高橋義和, 高橋昌宏, 城田英和, 高橋雅信, 蒲生真紀夫, 石岡千加史. 固形がんに合併した播種性血管内凝固症候群(DIC)に対する組換え型トロンボモデュリンアルファ(rTM)の治療成績に関する後ろ向き解析. 日本内科学会雑誌. 2018. 107. Suppl. 230-230
  • 川村 佳史, 今井 源, 西條 憲, 小峰 啓吾, 岡田 佳也, 大内 康太, 山田 英晴, 高橋 昌宏, 高橋 信, 高橋 雅信, et al. 骨転移を伴う消化器癌及び希少がん患者における、デノスマブとゾレドロン酸の効果比較. 日本癌治療学会学術集会抄録集. 2017. 55回. P40-6
  • 平出 桜, 小峰 啓吾, 佐藤 悠子, 大内 康太, 岡田 佳也, 今井 源, 西條 憲, 高橋 昌宏, 高橋 信, 城田 英和, et al. 進行・再発尿膜管癌に対しFOLFIRIおよびmFOLFOX6療法を施行した5症例の検討. 日本癌治療学会学術集会抄録集. 2017. 55回. P50-1
  • 梅垣 翔, 沖田 啓, 今井 源, 高橋 秀和, 大堀 久詔, 大内 康太, 蒲生 真紀夫, 山田 英晴, 笠原 佑記, 近松 園子, et al. HER2陽性進行・再発胃癌に対するtrastuzumab併用化学療法に関する検討. 日本癌治療学会学術集会抄録集. 2017. 55回. P84-5
more...
Patents (1):
Professional career (1):
  • Doctor of Philosophy (Tohoku University)
Awards (2):
  • 2016/10 - Cancer Science Young Scientist Award DNA methylation status as a biomarker of anti-EGFR treatment for metastatic colorectal cancer
  • 2015/11 - ESMO Asia 2015 Travel Grant DNA methylation profile can predict the clinical outcomes of anti-EGFR therapy for metastatic colorectal cancer
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page